Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

Inclusion Criteria: Part 1 (HVs only): * Healthy male volunteers, aged between 21 and 55 years inclusive * Participants with a negative hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), hepatitis C antibody, and human immunodeficiency virus (HIV) test result * Participants who have been vaccinated against hepatitis B * No evidence of Neisseria meningococci in nasopharyngeal swab * Neisseria meningitidis vaccination against serogroups B and A, C, W, and Y * Non-smokers, or former smokers, who have not smoked for at least 60 days prior to screening Parts 2, 3 and 4 (PNH participants only): * Male or female participants with PNH between 18 and 75 years of age * Neisseria meningitidis vaccination in accordance with most current local guidelines or standard of care (SOC) for participants at increased risk for meningococcal disease (Part 2 and 4) * Participant has been vaccinated with Neisseria meningitidis vaccine(s) in accordance with most current local guidelines or SOC for participants at increased risk for meningococcal disease or is being revaccinated if applicable (Part 3 and 4) * Antibiotic prophylaxis for meningococcal infection must be initiated prior to initiation of crovalimab therapy if the time period between initial Neisseria meningitidis vaccination and first dose of crovalimab is less than 2 weeks (Part 2 and 4) * Antibiotic prophylaxis of meningococcal infection may be initiated prior to initiation of crovalimab therapy based on local gui…